2022
In vitro and in vivo NMR based metabolomics in Parkinson's disease
Chaudhary S, Kumari S, Kumaran S, Goyal V, Jain S, Kaloiya G. In vitro and in vivo NMR based metabolomics in Parkinson's disease. Journal Of Magnetic Resonance Open 2022, 10: 100050. DOI: 10.1016/j.jmro.2022.100050.Peer-Reviewed Original ResearchNon-motor symptomsParkinson's diseaseMetabolic alterationsCognitive impairmentCommon non-motor symptomCerebral metabolic alterationsPathophysiological progressionPD subgroupsEarly diagnosisEarly changesDisease pathophysiologyBrain metabolitesSpecific biomarkersNeurodegenerative diseasesDiseaseMagnetic resonance spectroscopy techniquesSymptomsImpairmentAlterationsNon-invasive characterizationPathophysiologyDementiaDiagnosisProgressionBiomarkers
2020
Frontal lobe metabolic alterations characterizing Parkinson’s disease cognitive impairment
Chaudhary S, Kumaran S, Goyal V, Kalaivani M, Kaloiya G, Sagar R, Mehta N, Srivastava A, Jagannathan N. Frontal lobe metabolic alterations characterizing Parkinson’s disease cognitive impairment. Neurological Sciences 2020, 42: 1053-1064. PMID: 32729012, DOI: 10.1007/s10072-020-04626-9.Peer-Reviewed Original ResearchConceptsFrontal gray matterParkinson's disease cognitive impairmentN-acetyl aspartateHealthy controlsGray matterCognitive impairmentMetabolic alterationsFrontal WMLC Model softwareProton magnetic resonance spectroscopic imagingFrontal white matter regionsCognitive biomarkersCholinergic neural transmissionPD-CN groupsMagnetic resonance spectroscopic imagingWhite matter regionsNeuro-metabolismPD dementiaFunctional impairmentPD-CIFunction lossNeural transmissionTotal creatineNormal cognitionTotal choline